Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomized, Parallel-Group, Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis
Brief Summary: Phase 1 randomized, open-label, multicenter, parallel-group study designed to evaluate efficacy, pharmacokinetics and safety between CT-P13 subcutaneous (SC) and CT-P13 intravenous (IV) in patients with active Crohn's Disease (CD) and active Ulcerative Colitis (UC).


Options:
A: Arm Label: CT-P13 - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: CT-P13 - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13, Biological: Remicade | Arm Label: Remicade - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: Remicade | Arm Label: Remicade - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13, Biological: Remicade | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): CT-P13 - CT-P13, CT-P13 - Remicade, Remicade - CT-P13 | Intervention Type: BIOLOGICAL; Name: Remicade; Assigned to Arm(s): CT-P13 - Remicade, Remicade - CT-P13, Remicade - Remicade
B: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Biological: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cohort 1: CT-P13 IV 5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13 | Arm Label: Cohort 2: CT-P13 SC 120 mg; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: Cohort 3: CT-P13 SC 180 mg; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: Cohort 4: CT-P13 SC 240 mg; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: Arm 1: CT-P13 SC 120/240 mg; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: Arm 2: CT-P13 IV 5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13 | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Cohort 1: CT-P13 IV 5 mg/kg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Cohort 2: CT-P13 SC 120 mg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Cohort 3: CT-P13 SC 180 mg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Cohort 4: CT-P13 SC 240 mg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Arm 1: CT-P13 SC 120/240 mg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Arm 2: CT-P13 IV 5 mg/kg
D: Arm Label: INFLIXIMAB AND ANTI METABOLITE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: STOP INFLIXIMAB CONTINUING ANTI METABOLITE; Type: OTHER; Interventions: Drug: INFLIXIMAB | Arm Label: CONTINUING INFLIXIMAB AND discontinuing anti-metabolites; Type: OTHER; Interventions: Drug: AZATHIOPRINE, Drug: MERCAPTOPURINE, Drug: Methotrexate | Intervention Type: DRUG; Name: INFLIXIMAB; Assigned to Arm(s): STOP INFLIXIMAB CONTINUING ANTI METABOLITE | Intervention Type: DRUG; Name: AZATHIOPRINE; Assigned to Arm(s): CONTINUING INFLIXIMAB AND discontinuing anti-metabolites | Intervention Type: DRUG; Name: MERCAPTOPURINE; Assigned to Arm(s): CONTINUING INFLIXIMAB AND discontinuing anti-metabolites | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): CONTINUING INFLIXIMAB AND discontinuing anti-metabolites

Answer: C